Mark W. Frohlich
Amministratore Delegato presso Indapta Therapeutics, Inc.
Posizioni attive di Mark W. Frohlich
Società | Posizione | Inizio | Fine |
---|---|---|---|
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | 24/06/2019 | - |
Neuvogen, Inc. | Direttore/Membro del Consiglio | 23/08/2021 | - |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | Direttore/Membro del Consiglio | 10/02/2022 | - |
Amministratore Delegato | 10/02/2022 | - |
Storia della carriera di Mark W. Frohlich
Precedenti posizioni note di Mark W. Frohlich
Società | Posizione | Inizio | Fine |
---|---|---|---|
JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01/02/2014 | 01/09/2017 |
DENDREON CORPORATION | Direttore Tecnico/Scientifico/R&S | 01/08/2005 | 01/02/2014 |
Xcyte Therapies, Inc. | Direttore Tecnico/Scientifico/R&S | 01/10/2001 | 01/07/2005 |
The University of California, San Francisco | Corporate Officer/Principal | 01/01/1998 | 01/01/2001 |
Formazione di Mark W. Frohlich
Yale University | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 10 |
Posizioni
Director/Board Member | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 6 |
Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 6 |
---|---|
Xcyte Therapies, Inc. | Health Technology |
Dendreon Corp.
Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Juno Therapeutics, Inc.
Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | Health Technology |
Neuvogen, Inc. | |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | Health Technology |
- Borsa valori
- Insiders
- Mark W. Frohlich
- Esperienza